Skip to main content
. 2015 Oct 26;6(35):38166–38180. doi: 10.18632/oncotarget.6241

Figure 2. Glycolytic and hypoxic tumour volumes following treatment with cetuximab and bevacizumab.

Figure 2

18F-FDG tumour glycolytic volumes of A. HT-29 and B. LIM1215 tumours following treatment with PBS, cetuximab, bevacizumab, or combination. 18FMISO PET hypoxic tumour volumes of C. HT-29 and D. LIM1215 tumours following treatment with PBS, cetuximab, bevacizumab, or combination.